Cellectis (NASDAQ:CLLS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a research report report published on Thursday morning. The brokerage issued a buy rating on the biotechnology company’s stock.

Separately, Barclays reduced their target price on Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th.

Cellectis Stock Performance

CLLS stock opened at $1.29 on Thursday. Cellectis has a twelve month low of $1.24 and a twelve month high of $3.38. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The company has a market cap of $71.70 million, a P/E ratio of -0.99 and a beta of 3.06. The business’s fifty day moving average is $1.60 and its 200-day moving average is $1.88.

Hedge Funds Weigh In On Cellectis

Institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN raised its stake in Cellectis by 103.4% during the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock worth $44,000 after buying an additional 12,500 shares during the period. Millennium Management LLC bought a new stake in shares of Cellectis in the fourth quarter worth about $962,000. Finally, B Group Inc. acquired a new stake in shares of Cellectis during the fourth quarter worth about $5,547,000. Institutional investors and hedge funds own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.